Response of luteinizing hormone secreting pituitary adenoma to a long-acting somatostatin analogue

1988 ◽  
Vol 118 (4) ◽  
pp. 587-590 ◽  
Author(s):  
P. Vos ◽  
R.J. M. Croughs ◽  
J. H. H. Thijssen ◽  
J. W. van 't Verlaat ◽  
L. A. van Ginkel
Keyword(s):  
Pituitary Tumour ◽  
Biologically Active ◽  
Alpha Subunit ◽  
Medical Attention ◽  
Plasma Testosterone ◽  
Somatostatin Analogue ◽  
Grand Mal ◽  
Basal Plasma ◽  
Transsphenoidal Operation ◽  
Long Acting

Abstract. A large pituitary tumour was discovered in a 20 year old man who came to medical attention bacause of grand-mal seizures. The tumour produced biologically active LH as demonstrated by supranormal plasma LH and plasma testosterone values. Free alpha-subunit values were also elevated. In contrast, plasma FSH was in the lower normal range. Transsphenoidal operation failed to remove all tumour tissue. Detailed studies were carried out in the postoperative period. TRH and GnRH administration were associated with a rise of plasma LH and alpha-subunit, whereas plasma FSH was low and unresponsive. Bromocriptine treatment was ineffective. In contrast, both during and after treatment with SMS 201-995 for 6 weeks, a decrease of basal plasma LH values was observed. Furthermore, the administration of a single dose of SMS 201-995 reproducibly induced a decrease of plasma LH lasting for a period of about 6 h. The study suggests that SMS 201-995 may be useful in the treatment of patients with gonadotrope cell adenomas.

Hyperthyroidism due to non-tumoural inappropriate TSH secretion

1986 ◽  
Vol 113 (1) ◽  
pp. 42-46 ◽  
Author(s):  
Gareth Williams ◽  
Marius Kraenzlin ◽  
Laurence Sandier ◽  
Jacky Burrin ◽  
Adam Law ◽  
...  
Keyword(s):  
Pituitary Tumour ◽  
Somatostatin Analogues ◽  
Molar Ratio ◽  
Somatostatin Analogue ◽  
Axial Tomography ◽  
Α Subunit ◽  
Tsh Secretion ◽  
Long Acting ◽  
Inappropriate Tsh Secretion ◽  
Tsh Levels

Abstract. Inappropriate hypersecretion of TSH was investigated in a 25 year old man whose hyperthyroidism had relapsed 4 years after subtotal thyroidectomy. Serum TSH levels were further increased by both TRH and metoclopramide and were partially suppressed by triiodothyronine (120 μ/day). The serum α-subunit: TSH molar ratio was < 1.0, and computerised axial tomography showed no evidence of a pituitary tumour. These features are characteristic of inappropriate TSH secretion due to thyrotroph resistance to thyroid hormones. A long-acting somatostatin analogue (SMS 201-995), 50 μg injected sc twice-daily for three days, suppressed TSH levels and nearly normalised thyroid hormone levels. Somatostatin analogues may be therapeutically useful in thyrotoxicosis due to non-tumoural inappropriate TSH hypersecretion.

The effect of the long-acting somatostatin analogue SMS 201–995 on ACTH secretion in Nelson's syndrome and Cushing's disease

1989 ◽  
Vol 120 (6) ◽  
pp. 760-766 ◽  
Author(s):  
Steven W.J. Lamberts ◽  
Piet Uitterlinden ◽  
Jan M. G. Klijn
Keyword(s):  
Cushing’S Disease ◽  
Pituitary Tumour ◽  
Cushing's Disease ◽  
Somatostatin Analogue ◽  
Plasma Acth ◽  
Nelson’S Syndrome ◽  
Nelson's Syndrome ◽  
Chronic Therapy ◽  
Long Acting ◽  
Field Defect

Abstract. Chronic therapy of a patient with Nelson's syndrome for 2 years with 300 μg SMS 201–995 per day resulted in a significant decrease in circulating ACTH levels, normalization of the visual field defect and of loss of visual acuity of one eye, and stabilization of tumour growth, without radiological evidence of shrinkage of the pituitary tumour. In two other patients with Nelson's syndrome, SMS 201–995 acutely inhibited circulating ACTH levels. This effect could be shown best if cortisol replacement was temporarily withheld. SMS 201–995 did not affect plasma ACTH and cortisol levels in three patients with untreated Cushing's disease.

Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995)

1991 ◽  
Vol 124 (5) ◽  
pp. 487-491 ◽  
Author(s):  
André Warnet ◽  
Elisabeth Lajeunie ◽  
Françoise Gelbert ◽  
Michèle Duet ◽  
Philippe Chanson ◽  
...  
Keyword(s):  
Adverse Reactions ◽  
Pituitary Tumour ◽  
Somatostatin Analogue ◽  
Line Treatment ◽  
First Line ◽  
Sustained Improvement ◽  
Octreotide Therapy ◽  
Long Acting ◽  
Analogue Octreotide ◽  
First Line Treatment

Abstract. The long-acting somatostatin agonist octreotide can control TSH hypersecretion from most thyrotropic adenomas. Octreotide therapy has even been shown to improve chiasmal dysfunction. We report another patient in whom octreotide therapy was associated with gradual suppression of TSH hypersecretion, which escaped partially, dramatic and very rapid and sustained improvement of chiasm compression, and dramatic and sustained shrinkage of an unresectable TSH-secreting pituitary tumour. Unusual and prolonged gastrointestinal adverse reactions eventually disappeared except for steatorrhea. In conclusion, octreotide may be considered as first line treatment in patients with unresectable thyrotropic adenomas.

INFLUENCE OF METYRAPONE ON PLASMA CONCENTRATIONS OF TESTOSTERONE AND ANDROSTENEDIONE IN MAN

1971 ◽  
Vol 68 (3) ◽  
pp. 576-584 ◽  
Author(s):  
K. O. Nilsson ◽  
B. Hökfelt
Keyword(s):  
Body Weight ◽  
Male Patient ◽  
Gradual Increase ◽  
Plasma Concentrations ◽  
Plasma Testosterone ◽  
Testosterone Levels ◽  
Basal Plasma ◽  
Normal Males ◽  
A Minor ◽  
Secondary Hypogonadism

ABSTRACT Metyrapone was administered either orally, 750 mg every four h, in a total of six doses, or intravenously 30 mg per kg body weight as a four h infusion. In three males with normal endocrine functions, metyrapone given orally or intravenously induced a fall in plasma testosterone and an elevation of androstenedione within 2–8 h. When metyrapone was administered to a patient given dexamethasone to suppress endogenous ACTH production, the androstenedione levels did not alter whereas the testosterone levels showed a slight, transient decrease. In two normal females metyrapone administration was followed by a marked increase in plasma androstenedione whereas testosterone showed only a minor, gradual increase. In one male patient with Addison's disease the basal plasma testosterone was normal whereas the level of androstenedione was low. Following metyrapone intravenously, there was a slight suppression of plasma testosterone but no change in the androstenedione concentration. In one patient with primary hypogonadism, two with secondary hypogonadism and two with Klinefelter's syndrome the plasma testosterone was low under basal conditions and did not change following metyrapone. Basal plasma androstenedione was within the range for normal males and increased markedly following metyrapone in all the cases.

scholarly journals Successful treatment with a long-acting somatostatin analogue(SMS201-995) in a patient with malignant carcinoid syndrome.

1988 ◽  
Vol 27 (3) ◽  
pp. 311-316 ◽  
Author(s):  
Masayuki TSUDA ◽  
Shigehisa TAMAKI ◽  
Eiichi IWASAKI ◽  
Seikou MURASHIMA ◽  
Katsumi DEGUCHI ◽  
...  
Keyword(s):  
Successful Treatment ◽  
Carcinoid Syndrome ◽  
Somatostatin Analogue ◽  
Malignant Carcinoid ◽  
Malignant Carcinoid Syndrome ◽  
Long Acting

Effective Therapy of Insulinoma by Using Long-Acting Somatostatin Analogue. A Case Report and Literature Review

2011 ◽  
Vol 120 (02) ◽  
pp. 68-72 ◽  
Author(s):  
A. Jawiarczyk ◽  
M. Bolanowski ◽  
J. Syrycka ◽  
G. Bednarek-Tupikowska ◽  
M. Kałużny ◽  
...  
Keyword(s):  
Adrenal Gland ◽  
Somatostatin Receptors ◽  
Subcutaneous Administration ◽  
Pancreatic Neuroendocrine Tumor ◽  
Somatostatin Analogue ◽  
Left Adrenal Gland ◽  
Glucose Levels ◽  
Long Acting ◽  
The Right

AbstractWe are reporting a case of 68-year-old woman with insulinoma, after a non-successful tumor surgery and a long-term diazoxide treatment. She had a lot of hypoglycemia cases, and a weight gain of 50 kg. An abdominal CT scan demonstrated a tumor 28 mm in the diameter, in the head of the pancreas. The patient did not agree for the repeated insulinoma surgery. Furthermore, we found a lesion in the left adrenal gland (14 mm in the diameter) and in the right lung (8 mm in the diameter). Pheochromocytoma was diagnosed on the basis of hypertension, elevated levels of normetanephrine in the 24-h urine collection, and an elevated level of norepinephrine in a plasma sample. After the left adrenal gland removal we observed lower blood pressure. Since we had revealed the presence of somatostatin receptors by the somatostatin receptors scintigraphy, we decided to control hypoglycemia by a monthly subcutaneous administration of the long-acting lanreotide. Because of higher glucose levels (300–400 mg/dl) we started an intense insulin therapy. Nowadays, the patient feels better, she has lost 20 kg of her body weight, and we have observed normal blood glucose levels during the long-term lanreotide treatment. We have noticed neither side effects nor hypoglycemic episodes and we have reduced the dose of insulin. The presented case can be an evidence of the effective treatment of the pancreatic neuroendocrine tumor of insulinoma type, with somatostatin analogue.

Effect of Octreotide, a Long-Acting Somatostatin Analogue, on Plasma Amino Acid Uptake by the Pancreas

Pancreas ◽  
1991 ◽  
Vol 6 (6) ◽  
pp. 668-672 ◽  
Author(s):  
L. Gullo ◽  
R. Pezzilli ◽  
Dvora Ancona ◽  
A. Morselli Labate ◽  
L. Barbara
Keyword(s):  
Amino Acid ◽  
Amino Acid Uptake ◽  
Plasma Amino Acid ◽  
Somatostatin Analogue ◽  
Acid Uptake ◽  
Long Acting

scholarly journals Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors

2019 ◽  
Vol 10 (7) ◽  
Author(s):  
Jordan Gabrielsen, PharmD ◽  
Gianna Girone, PharmD ◽  
Bonita Bennett, BSN ◽  
Anna Jung, PharmD, BCPS
Keyword(s):  
Neuroendocrine Tumors ◽  
Safety Monitoring ◽  
Somatostatin Analogue ◽  
Monitoring Protocol ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document